FTC Submission: Competition and Consumer Protection in the 21st Century
Overpatented, Overpriced: Enbrel Special Edition
Overpatented, Overpriced: Lantus Special Edition
Overpatented, Overpriced: Special Humira Edition
I-MAK Submission to FTC on the Role of Intellectual Property
Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices
Overpatented: Stats on the Top Selling Drugs
2017 Annual Report
Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Submission to Health and Human Services: I-MAK response to Blueprint to Lower Drug Prices